M
Marcia L. Moss
Researcher at Research Triangle Park
Publications - 61
Citations - 5536
Marcia L. Moss is an academic researcher from Research Triangle Park. The author has contributed to research in topics: ADAM10 & ADAM Proteins. The author has an hindex of 35, co-authored 61 publications receiving 5288 citations. Previous affiliations of Marcia L. Moss include Bielefeld University & University of Wisconsin-Madison.
Papers
More filters
Journal ArticleDOI
Cloning of a disintegrin metalloproteinase that processes precursor tumour-necrosis factor-alpha.
Marcia L. Moss,S.-L. Catherine Jin,Marcos E. Milla,William Burkhart,H. Luke Carter,Wen-Ji Chen,William C. Clay,John R. Didsbury,Daniel F. Hassler,Christine R. Hoffman,Thomas A. Kost,Millard H. Lambert,M. Anthony Leesnitzer,Philip McCauley,Gerard McGeehan,Justin L. Mitchell,Mary Pat Moyer,Gregory Pahel,Warren J. Rocque,Laurie K. Overton,Frank J Schoenen,Theresa D. Seaton,Jui-Lan Su,Janet Warner,Derril H. Willard,J. David Becherer +25 more
TL;DR: The expression of recombinant TACE results in the production of functional enzyme that correctly processes precursor TNF-α to the mature form, and provides a readily available source of enzyme to help in the search for new anti-inflammatory agents that target the final processing stage of T NF-α production.
Journal ArticleDOI
Metalloprotease-Disintegrin MDC9: Intracellular Maturation and Catalytic Activity
Monireh Roghani,J. David Becherer,Marcia L. Moss,Ruth E. Atherton,Hediye Erdjument-Bromage,Joaquín Arribas,R. Kevin Blackburn,Gisela Weskamp,Paul Tempst,Carl P. Blobel,Carl P. Blobel +10 more
TL;DR: The analysis of the intracellular maturation and catalytic activity of the widely expressed metalloprotease disintegrin MDC9 suggests that removal of the inhibitory pro-domain of M DC9 by a furin-type pro-protein convertase in the secretory pathway is a prerequisite for protease activity.
Journal ArticleDOI
Drug insight: tumor necrosis factor-converting enzyme as a pharmaceutical target for rheumatoid arthritis.
TL;DR: Preclinical and clinical findings regarding the use of inhibitors of TNF-converting enzyme for the treatment of rheumatoid arthritis are summarized.
Journal ArticleDOI
Endotoxin induces rapid metalloproteinase-mediated shedding followed by up-regulation of the monocyte hemoglobin scavenger receptor CD163.
Katharine A. Hintz,Athos J. Rassias,Kathleen Wardwell,Marcia L. Moss,Peter M. Morganelli,Peter M. Morganelli,Patricia A. Pioli,Alice L. Givan,Paul K. Wallace,Mark P. Yeager,Paul M. Guyre +10 more
TL;DR: It is shown that CD163 is rapidly mobilized in response to bacterial endotoxin, and studies using the inhibitor TAPI‐0 indicate that a metalloproteinase is responsible for LPS‐mediated shedding of CD163.
Journal ArticleDOI
Species Specificity of ADAM10 and ADAM17 Proteins in Interleukin-6 (IL-6) Trans-signaling and Novel Role of ADAM10 in Inducible IL-6 Receptor Shedding
Christoph Garbers,Nathalie Jänner,Athena Chalaris,Marcia L. Moss,Doreen M. Floss,Dörte Meyer,Friedrich Koch-Nolte,Stefan Rose-John,Jürgen Scheller +8 more
TL;DR: An unexpected species specificity of ADAM10 and ADAM17 is described andADAM10 is identified as novel inducible sheddase of IL-6R in mice and humans, which might have consequences for the interpretation of phenotypes from ADAM 17- and ADam10-deficient mice.